IMPACT OF ANTICOAGULANT THERAPY ON HEMOSTATIC AND INFLAMMATORY MARKERS IN PATIENTS WITH IMMUNE-MEDIATED MICROVASCULAR THROMBOSIS
Keywords:
Immune-mediated microvascular thrombosis, anticoagulant therapy, hemostatic parameters, D-dimer, fibrinogen, C-reactive protein, interleukin-6.Abstract
Immune-mediated microvascular thrombosis (IMMT) is a complex disorder driven by immune dysregulation, leading to microvascular occlusion and necessitating anticoagulant therapy. This study evaluates the impact of anticoagulant therapy on hemostatic parameters (D-dimer, fibrinogen, prothrombin time [PT], activated partial thromboplastin time [APTT]) and inflammatory markers (C-reactive protein [CRP], interleukin-6 [IL-6]) in 45 patients with IMMT. Patients were followed for 12 months, receiving either warfarin or direct oral anticoagulants (DOACs). D-dimer levels decreased significantly (1.5 µg/mL to 0.6 µg/mL, p<0.01), with DOACs showing greater reduction (p=0.02). Fibrinogen remained elevated in 60% of patients (mean 4.3 ± 0.9 g/L), correlating with CRP (r=0.65, p<0.01). IL-6 levels declined from 12.5 pg/mL to 5.8 pg/mL (p<0.05), reflecting reduced inflammation. Thrombotic recurrence occurred in 18% of patients, associated with persistent fibrinogen elevation (OR 2.9, 95% CI 1.1–7.6, p=0.03). These findings highlight the role of hemostatic and inflammatory markers in monitoring therapy efficacy and predicting outcomes in IMMT, supporting personalized treatment approaches.
References
1. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019-1027. doi:10.1002/art.10187
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x
3. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med. 2017;377(12):1177-1187. doi:10.1056/NEJMra1700365
4. Lippi G, Favaloro EJ. D-dimer measurement and laboratory feedback. J Thromb Haemost. 2017;15(7):1453-1456. doi:10.1111/jth.13706
5. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk. J Am Coll Cardiol. 2007;49(21):2129-2138. doi:10.1016/j.jacc.2007.02.054
6. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026
7. Pagnoux C, Cohen P, Guillevin L. Vasculitides: classification, clinical features, and management. Curr Opin Rheumatol. 2010;22(1):1-8. doi:10.1097/BOR.0b013e328333d7e3
8. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi:10.1002/art.37715
9. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405
10. Favaloro EJ, Lippi G. Laboratory testing in the era of direct oral anticoagulants: a practical guide. Semin Thromb Hemost. 2015;41(3):277-291. doi:10.1055/s-0035-1546827
11. Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol. 2017;70(19):2411-2420. doi:10.1016/j.jacc.2017.09.024
12. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26-S34. doi:10.1097/CCM.0b013e3181c98d21
13. Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41(1):206-232. doi:10.1007/s11239-015-1310-7
14. Hunter CA, Jones SA. IL-6 as a keystone cytokine in immune regulation. Nat Immunol. 2015;16(5):448-457. doi:10.1038/ni.3133
15. Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121(13):1523-1532. doi:10.1161/CIRCULATIONAHA.109.853119
16. Korte W, Riesen WF. Fibrinogen and cardiovascular risk. Semin Thromb Hemost. 2000;26(3):323-327. doi:10.1055/s-2000-8467
17. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767-1772. doi:10.1161/01.cir.101.15.1767
18. Tripodi A, Mannucci PM. Laboratory monitoring of anticoagulation: where do we stand? Semin Thromb Hemost. 2009;35(1):34-41. doi:10.1055/s-0029-1214146
